Related Experiment Video
Updated: Feb 19, 2026
07:09
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
8.0K
Teaching an old pathway new tricks: Targeting BTK to block NLRP3
1Department of Pediatrics, Allergy Immunology Division, the Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA 19104, USA.
Science Immunology
|November 5, 2017
Summary
A proteomics screen identified Bruton's tyrosine kinase (BTK) as a key regulator of inflammasomes. Blocking BTK effectively inhibits inflammasome activity, offering a new therapeutic target.
Area of Science:
- Immunology
- Molecular Biology
- Biochemistry
Background:
- Inflammasomes are multi-protein complexes crucial for innate immunity and inflammatory diseases.
- Dysregulated inflammasome activation is implicated in various pathologies.
Purpose of the Study:
- To identify novel regulators of inflammasome activation using a proteomics approach.
- To investigate the role of Bruton's tyrosine kinase (BTK) in inflammasome signaling.
Main Methods:
- Proteomics screening to identify novel protein interactions.
- Biochemical assays to assess inflammasome activity.
- Inhibition studies targeting BTK.
Main Results:
- Bruton's tyrosine kinase (BTK) was identified as a novel inflammasome regulator.
- BTK plays a significant role in controlling inflammasome assembly and activation.
- Pharmacological inhibition of BTK effectively suppressed inflammasome activity.
Conclusions:
- BTK is a critical component of the inflammasome pathway.
- Targeting BTK presents a promising strategy for modulating inflammasome-driven inflammation.
- This discovery opens new avenues for treating inflammatory disorders.
